Ceapro (CRPOF) News Today → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free CRPOF Stock Alerts $0.17 -0.03 (-15.00%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 7:24 AM | americanbankingnews.comCeapro (OTCMKTS:CRPOF) Announces Quarterly Earnings ResultsMay 29 at 9:00 AM | globenewswire.comCeapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateApril 29, 2024 | globenewswire.comCeapro Inc. Reports 2023 Financial Results and Operational HighlightsMarch 28, 2024 | finanznachrichten.deAeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna ZentarisMarch 28, 2024 | globenewswire.comCeapro Receives Final Court Approval for Merger with Aeterna ZentarisMarch 12, 2024 | globenewswire.comAeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsFebruary 26, 2024 | globenewswire.comLeading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical CompanyFebruary 23, 2024 | globenewswire.comCeapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base BusinessFebruary 15, 2024 | globenewswire.comCeapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna ZentarisDecember 13, 2023 | finance.yahoo.comCeapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based DiseasesNovember 29, 2023 | msn.comCeapro GAAP EPS of -C$0.01, revenue of C$2.62MNovember 7, 2023 | finance.yahoo.comCeapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) TechnologyJuly 18, 2023 | finance.yahoo.comCeapro Announces Next Phase of Research Collaboration with the Angiogenesis FoundationJune 7, 2023 | finanznachrichten.deCeapro Inc.: Ceapro Announces Results of 2023 Shareholders' MeetingJune 7, 2023 | finance.yahoo.comCeapro Announces Results of 2023 Shareholders’ MeetingApril 27, 2023 | finance.yahoo.comCeapro Inc. Appoints Michel Regnier as Senior Vice President, Technical OperationsApril 26, 2023 | theglobeandmail.comClosing Bell: Ceapro Inc flat on Tuesday (CZO)April 25, 2023 | theglobeandmail.comClosing Bell: Ceapro Inc flat on Monday (CZO)April 13, 2023 | theglobeandmail.comClosing Bell: Ceapro Inc down on Thursday (CZO)March 23, 2023 | finance.yahoo.comCeapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International ConferenceMarch 14, 2023 | finance.yahoo.comCeapro Inc. (CRPOF) Stock Historical Prices & Data - Yahoo FinanceMarch 8, 2023 | finance.yahoo.comCeapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American SocietyFebruary 21, 2023 | finance.yahoo.comCeapro Inc. Recognized as a Top 50 TSX Venture Exchange CompanyJanuary 10, 2023 | finance.yahoo.comCeapro to Present at the Virtual Investor 2023 Companies to Watch EventDecember 22, 2022 | msn.comCeapro receives approval to begin human trial for anti-inflammatory drugDecember 22, 2022 | technews.tmcnet.comCeapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide TabletsNovember 9, 2022 | finance.yahoo.comCeapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational HighlightsNovember 7, 2022 | finance.yahoo.comCeapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical MarketsAugust 26, 2022 | ca.finance.yahoo.comCeapro Lone Stock at 52-Week HighAugust 11, 2022 | financialpost.comCeapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic/-Prophylactic for COVID-19-Induced Lung FibrosisAugust 9, 2022 | finance.yahoo.comCeapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical FluidsMay 23, 2022 | finance.yahoo.comCeapro Inc. to Present at the H.C. Wainwright Global Investment ConferenceMay 13, 2022 | benzinga.comCeapro Inc. Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical FluidsMarch 10, 2022 | financialpost.comCeapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, SymriseJanuary 20, 2022 | benzinga.comCeapro Inc. to Present at the Virtual Investor 2022 Top Picks ConferenceNovember 29, 2021 | finance.yahoo.comCeapro Inc. Announces R&D Funding to Support PGX Technology ProjectNovember 17, 2021 | finance.yahoo.comCeapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational HighlightsNovember 17, 2021 | finance.yahoo.comCeapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol LevelsNovember 11, 2021 | finance.yahoo.comCeapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta Glucan Processed with Pressurized Gas eXpanded Technology (PGX-YBG)October 26, 2021 | finance.yahoo.comCeapro Inc.'s (CVE:CZO) Has Performed Well But Fundamentals Look Varied: Is There A Clear Direction For The Stock?August 26, 2021 | finance.yahoo.comCeapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational HighlightsAugust 24, 2021 | apnews.comCeapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan ...August 13, 2021 | au.finance.yahoo.comGlobal Electric Vehicle Outlook 2021 Get Ceapro News Delivered to You Automatically Sign up to receive the latest news and ratings for CRPOF and its competitors with MarketBeat's FREE daily newsletter. Email Address “This will be one of the biggest revolutions ever.” - NVIDIA CEO (Ad)NVIDIA's CEO calls it the "next amazing revolution"... The Economist says its a "boon to humanity"... And Jeff Bezos is heavily invested in it. A new breakthrough tech could add up to $20 trillion to the U.S. economy. CRPOF Media Mentions By Week CRPOF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRPOF News Sentiment▼-0.560.78▲Average Medical News Sentiment CRPOF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRPOF Articles This Week▼40▲CRPOF Articles Average Week Get Ceapro News Delivered to You Automatically Sign up to receive the latest news and ratings for CRPOF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vincerx Pharma News Flora Growth News Inhibitor Therapeutics News Purple Biotech News Kiora Pharmaceuticals News MIRA Pharmaceuticals News Oncotelic Therapeutics News Pieris Pharmaceuticals News Edesa Biotech News Galecto News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CRPOF) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ceapro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.